Executive appointments at Merck KGaA and Pharmalink

15 November 2011

Germany’s Merck KGaA (MRK: DE) has announced that Joachim Christ will join the company on January 1, 2012 as head of corporate controlling. He will report to Matthias Zachert, member of the executive board of Merck and chief financial officer.

Mr Zachert commented: “Because of his past positions at Hoechst, Aventis and Lanxess, Joachim Christ has extensive experience in both the pharmaceutical and chemical industries as well as in the controlling function. He is ideally qualified to develop the Controlling function at Merck into a true partner to our businesses. One of our overriding aims is to further develop and substantially modernize our finance organization.”

Pharmalink names new chairman, makes board appointment

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK